BFHC Research — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$50,227	3
2022	Research	$1,113	3
2021	Research	$1,951	3
2020	Research	$1,731	6
2019	Research	$16,341	26

Breakdown

Who paid Research payments · program years 2019–2025

Amgen Inc. $39,261 2 payments
Kowa Research Institute, Inc. $15,137 6 payments
Pfizer Inc. $14,030 7 payments
Teva Pharmaceuticals USA, Inc. $1,471 1 payment
Radius Health, Inc. $1,464 25 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma $27,817 1 payment
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity $11,444 1 payment
An Interventional Phase 23 Adaptive Multicenter Randomized Doubleblind Study to Investigate Efficacy and Safety of Oral Sisunatovir Compared With Placebo in Nonhospitalized Symptomatic Adults With Respiratory Syncytial Virus Infection Who Are at Risk of Progression to Severe Illness $10,966 1 payment
K-877-303 $9,114 4 payments
K-877-301 $6,023 2 payments
A Phase 23 Randomized Doubleblind Doubledummy Placebo Controlled Study to Evaluate the Safety and Efficacy of 2 Regimens of Orally Administered PF 07321332Ritonavir in Preventing Symptomatic Sarscov2 Infection in Adult Household Contacts of An Individual With Symptomatic Covid19 $2,147 5 payments
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma $1,471 1 payment
A Randomized, Non-Inferiority, Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Abaloparatide-Smts for the Treatment of Postmenopausal Women With Osteoporosis $1,464 25 payments
An Interventional Efficacy and Safety Phase 23 Doubleblind 2Arm Study to Investigate Orally Administered Pf07321332ritonavir Compared With Placebo in Nonhospitalized Symptomatic Adult Participants With Covid19 Who Are at Increased Risk of Progressing to Severe Illness $917 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.